SGI
ONCT

Summit Global Investments’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Summit Global Investments’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-588
Closed -$56K – 587
2021
Q2 		$56K Hold
588
– – ﹤0.01% 555
2021
Q1 		$98K Buy
+588
New +$77.8K 0.01% 538

Other funds holding ONCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Summit Global Investments's ONCT Position: Q3 2021 in Review

Summit Global Investments sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2021, closing a stake of 588 shares — an estimated $56K sold.

Summit Global Investments first reported a position in ONCT in Q1 2021 and held it in 2 quarters. The position peaked at $98K in Q1 2021. 76 funds tracked by Wall St. Rank hold ONCT as of Q3 2021.

  • Summit Global Investments reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Summit Global Investments sold 588 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $56K.
  • Summit Global Investments first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Summit Global Investments's Oncternal Therapeutics, Inc. Common Stock position peaked at $98K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Summit Global Investments's 13F filing for Q3 2021, filed 8 Nov 2021.